Guizhou Yibai Pharmaceutical Co.,Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Guizhou Yibai Pharmaceutical Co., Ltd. is a high-tech enterprise that integrates the research, development, production, and sales of new drugs. The company was founded on June 12, 1995, and has been continuously developing and growing over the years. With strong support from the national, provincial, and municipal governments, the company successfully completed its shareholding transformation in 2000 and was successfully listed on the Shanghai Stock Exchange (securities code 600594) on March 8, 2004, becoming the first private enterprise to be listed in Guizhou Province. The company currently covers an area of nearly 484400 square meters, with a production plant that meets the National Good Manufacturing Practice (GMP) of 41200 square meters and a green area of 68700 square meters. The company's production lines for capsules, tablets, granules, syrups, small volume injections, freeze-dried powder injections, drop pills, oral solutions, etc. have all passed the national GMP certification, and all production lines have reached the advanced level in China. Yibai Pharmaceutical implements a group operation model and optimizes enterprise management. At present, Yibai Pharmaceutical has 8 production enterprises under its umbrella: Guizhou Yibai Pharmaceutical Co., Ltd., Hainan Chang'an International Pharmaceutical Co., Ltd., Yunnan Nanzhao Pharmaceutical Co., Ltd., Tianjin Zhongsheng Haitian Pharmaceutical Co., Ltd., Beijing Aide Pharmaceutical Co., Ltd., Guizhou Ethnic Pharmaceutical Co., Ltd., Guizhou Yibai Women's Pharmacy Co., Ltd., and Guizhou Yibai Traditional Chinese Medicine Formula Granules Co., Ltd. The Yibai medical sector has three hospitals: Mianyang Fulin Hospital, Deyang Cancer Hospital, and Liaoyang Zhongao Cancer Hospital. In 2021, the company achieved a revenue of 3.446 billion yuan and a tax payment of 380 million yuan. Since its listing, the company has paid nearly 6.6 billion yuan in taxes to the state. The company currently has nearly 7000 employees, of which 76% have a college degree or above. In March 2004, the company used 12 million yuan of learning funds to jointly run the school with the Antai School of Management at Shanghai Jiao Tong University, and established the Guiyang class of Antai School of Management at Shanghai Jiao Tong University. 50 middle-level management cadres of the company became EMBA students of the class, reserving management successors for the company's development. The company also sends professional and technical personnel to relevant pharmaceutical colleges for professional training, focusing on improving the company's technical strength and cultivating innovative spirit; Adhere to the worker training system and continuously enhance the cultural quality, cultivation, and technical skills of workers. All employees of the company will receive corresponding training strictly according to more than 300 class hours per year. At present, the company's main products include injectable Lobatin, Aidi Injection, Ginkgo Damo Injection (Xingding Injection), Compound Cantharidin Capsules (Kangsaidi Capsules), Baogong Zhixue Granules, Fuyanxiao Capsules, Jinlian Qingre Effervescent Tablets, Bilin Capsules and Granules, Keke Capsules, Shugan Yiyang Capsules, Jingulian Capsules, Aiyu Capsules, Xinwei Zhitong Capsules, Liqi Huoxue Droplets, etc. We have formed a series of advantageous tumor products, cardiovascular and cerebrovascular series products, maternal and child series products, as well as a comprehensive series of products in orthopedics, digestion, andrology, and urology. Among them, Loplatin for injection is a national first class new drug, the third generation platinum based anti-tumor drug for tumor chemotherapy. Compared with other platinum based anti-tumor drugs, it has the advantages of no nephrotoxicity, no ototoxicity, and no neurotoxicity, while also having no cross resistance with other platinum based drugs; Aidi Injection and Compound Cantharidin Capsules (Kangsaidi Capsules) are biphasic new anti-tumor drugs; The research on compound traditional Chinese medicine injection - Aidi injection has reached the genetic level; The fourth generation Ginkgo biloba preparation - Ginkgo biloba injection (Xingding injection) is an effective therapeutic drug for cardiovascular, cerebrovascular, and peripheral circulatory disorders. Its development and production have injected new vitality into the company; Baogong Zhixue Granule is a traditional Chinese medicine for treating gynecological dysfunctional uterine bleeding; Fuyanxiao Capsule is a classic medication for treating gynecological inflammation in Shen's gynecology department, and is a unique ethnic medicine along with Jingulian Capsules and Aiyu Capsules; Jinlian Qingre Effervescent Tablets are a unique dosage form and therapeutic drug developed by Academician Li Lianda through pharmacodynamic experiments on the basis of Baihu Tang and Zengye Tang. At present, the company is actively expanding its chemical drug market. We will focus on various approaches such as biomedicine and chemical drug imitation, innovative research and development, and other collaborations in the treatment fields of tumors, cardiovascular and cerebrovascular diseases, and women and children. In the future, Yibai will continue to focus on the field of pharmaceutical manufacturing, consolidate its main pharmaceutical industry, and form a comprehensive pharmaceutical enterprise that combines chemical medicine, traditional Chinese medicine, and biopharmaceuticals. At the same time, we are constantly expanding into the fields of medical services and big health products, forming a development situation of "one ship, two wings". For a long time, the company has attached great importance to the support role of technological innovation and research and development for enterprise development, emphasizing that "innovation is the driving force of the company's development". In 2005, the company was awarded the title of "National Excellent Private Science and Technology Innovation Enterprise".In 2006, it was approved by the National Development and Reform Commission, the Ministry of Science and Technology, the Ministry of Finance, and the General Administration of Customs Awarded by the National Taxation Bureau and other five ministries and commissions National Certified Enterprise Technology Center ". In 2006, the company was approved by the Ministry of Human Resources as an enterprise postdoctoral workstation. In 2007, with the approval of the Guizhou Provincial Department of Science and Technology, the company was established as the Guizhou Provincial New Drug Release System Engineering Technology Research Center and successfully passed the acceptance. In 2008, it was approved as a national level innovative pilot enterprise and was also rated as a high-tech enterprise in Guizhou Province. In 2008, with the approval of the Guizhou Provincial Development and Reform Commission, our company also obtained the Guizhou Provincial Ethnic Medicine Research Center The New Formulation Engineering Technology Center has received national funding and technical support. In 2009, the company was approved as a national level innovative enterprise, In the same year, it was approved by the National Development and Reform Commission to build the "National and Local Joint Engineering Technology Research Center for New Formulations of Southwest Ethnic Medicine", which also passed the acceptance inspection. In October 2014, the Ministry of Science and Technology of the People's Republic of China officially approved the construction of the "National Miao Medicine Engineering Technology Research Center" At present, this center is the first national engineering and technology research center for ethnic medicine in China, and also the first national level research and development platform in the field of traditional Chinese medicine and ethnic medicine in Guizhou Province. It fills the gap in the national engineering and technology research platform for the development of ethnic medicine industry and achieves a breakthrough in the national engineering and technology research center for ethnic Chinese medicine in Guizhou. The National Miao Medicine Engineering and Technology Research Center mainly focuses on the basic and application research of innovative drugs for Miao medicine, as well as the new formulation and agent of Miao medicine We have conducted comprehensive research on Miao medicine, including type research, secondary development of large varieties of Miao medicine, and protection and development of Miao medicine resources. We have achieved multiple research results and successfully passed the acceptance of the Ministry of Science and Technology of the People's Republic of China. On this basis, our company is actively increasing its product research and development efforts, and multiple projects in new product development and new dosage form research are being carried out in an orderly manner. At present, the company has a total of 41 varieties under research, including 13 cardiovascular and cerebrovascular products, 4 anti-tumor products, and 9 cold cough, heat clearing and detoxification products. The quality standard improvement and efficacy evaluation of the exclusive Miao medicine "Jingulian Capsule" produced by the company have been supported by the national key research plan. The exclusive Miao medicine new drug "Pearl Dropping Pill" developed by the company has received support from the national "13th Five Year Plan" major new drug development plan, and has completed the third phase of clinical research. We are now preparing to apply for production and listing. The various achievements of the company's new drug research and development will become strategic support points for the company's development, continuously injecting new vitality into the company. As a wholly-owned subsidiary of Yibai Group, Beijing Yibai Pharmaceutical Research Institute was registered and established in Beijing Zhongguancun Life Science Park in August 2018. Its historical mission is to promote the transformation of the group from traditional Chinese medicine preparations to a pharmaceutical enterprise group that focuses on research and development, production, circulation, and sales of traditional Chinese medicine, chemical medicine, and biopharmaceuticals. In the near future, Beijing Yibai Pharmaceutical Research Institute will establish its own laboratory and research and development team according to the group's development plan. The research and development projects will gradually shift from focusing on chemical generic drugs to innovative drugs, improved new drugs, sustained-release formulations, children's drugs, macromolecular drugs, and other high value-added products. The research and development method will gradually shift from external cooperation to a combination of independent research and development with external cooperation. Ultimately, a virtuous cycle of research and development, production, sales, and reinvestment within the group will be achieved, promoting the integration of technology and capital, and assisting the capital market. The company has always attached great importance to the protection of intellectual property. In 2004, a specialized intellectual property department was established and measures such as applying for patent protection and creating well-known trademarks were taken. The company focuses on developing core technologies and enhancing the company's independent innovation capabilities. As of the end of 2020, the company had applied for a total of 367 patents, and 170 have been authorized and remain valid, including 131 invention patents, 38 design patents, and 1 utility model. 370 trademarks have been applied for and 323 certificates have been obtained. The three main trademarks "Yibai", "Zuo Zuo Yibai", and "Ke Ke" have been registered in Madrid with countries and regions such as the United States, Canada, the United Kingdom, and Taiwan, resulting in a total of 34 international trademark registration certificates. Two trademarks, "Yibai" and "KEKE Keke", have been awarded as well-known trademarks in China. "Zuo Zuo Yibai", "Xingding", "Kangsaidi", and "Yibai Aidi" have been awarded as famous trademarks in Guizhou Province. Aidi Injection, Jingulian Capsules, and Loplatin for Injection have won the National Patent Excellence Award for three patents. In 2009, it was awarded the title of "National Enterprise and Institution Intellectual Property Pilot Unit", in 2012, it was awarded the first batch of "Intellectual Property Advantage Enterprises" in Guizhou Province, and in 2015, it was awarded the title of "National Intellectual Property Demonstration Enterprise". The company has also established an intellectual property management system and obtained the "Intellectual Property Management System Certification" in 2015.Yibai Pharmaceutical has always been committed to public welfare. In the early 2008 freezing disaster, Yibai immediately sent condolences to the people in the disaster area and donated 600000 yuan to support the disaster area; In the May 2008 Wenchuan earthquake disaster in Sichuan, we took the lead and donated a total of 1.24 million in cash and 1 million worth of drugs to our fellow victims in the disaster area; Eating water without forgetting to dig wells, Yibai Pharmaceutical has also fully participated in industrial poverty alleviation, employment poverty alleviation, and public welfare poverty alleviation in our province. In the early 2011 drought disaster in Guizhou, it donated 2.8 million yuan in cash; In 2013, a donation of 150000 yuan was made for the construction of public facilities in Dongfeng Gaoxue Village, Wudang District; In 2014, donated 1.45 million yuan in cultural and educational support to the Guizhou Provincial Museum of Culture and History; In 2016, I sponsored the 4th Guizhou People's Activity with a total of 1 million people. In 2013, the construction of a traditional Chinese medicine base in Luodian planted rare medicinal herbs - big fruit tree ginger seeds. The model of "company+cooperative+farmer" was adopted, which not only promoted the development of local industries, alleviated the supply of raw materials for enterprises, but also allowed impoverished farmers to gain wealth experience. At the beginning of 2020, all parts of the country will invest in combating the pneumonia epidemic caused by novel coronavirus, and many places still face a shortage of medical supplies. Charitable donations from all sectors of society are becoming an important supplement to alleviate the problem of material supply. As a leading enterprise in the pharmaceutical industry in Guizhou, Guizhou Yibai Pharmaceutical Co., Ltd. actively participates in the actual action against the epidemic. The company headquarters donated drugs worth 660000 yuan to your business association; Yibai's branches in various provinces and cities have donated over ten million yuan to medical units at all levels, including Jinlian Qingre Effervescent Tablets and medical supplies, effectively enhancing their care for society and their service capabilities for medical workers and patients. The company's mission is to be an excellent provider of modern pharmaceutical products and a leader in health and medical services. In the tide of the economic market, we adhere to the values of "Health 100, Quality 100, Gratitude 100, and Innovation 100", provide customers with high-quality, efficient, and environmentally friendly products, create the greatest wealth for investors, and create the greatest value for society. Continuously advancing towards the vision of becoming a respected and sustainable company in the Chinese pharmaceutical industry!. |
| Headquarter | Guiyang |
| Establish Date | 6/12/1995 |
| Listed Code | 600594.SH |
| Listed Date | 3/23/2004 |
| Chairman | Dou Qiling. |
| CEO | Dou Yaqi. |
| Website | www.gzcci.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
